Share ownership Dishman Carbogen Amcis Limited

DCAL

INE385W01011

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 03:58:44 23/01/2026 pm IST			5-day change	1st Jan Change
209.32 ^INR	-4.17%		-17.62%	-15.46%

27/12	Dishman Carbogen Amcis Limited Approves Issue of Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures Aggregating Up to INR 500 Million	CI
23/12	Dishman Carbogen Amcis to consider fund raising via NCDs	RE

Share class: Dishman Carbogen Amcis Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	15,67,83,095	4,64,98,251 ( 29.66 %)	0	29.66 %

Major shareholders: Dishman Carbogen Amcis Limited

Name	Equities	%	Valuation
Adimans Technologies LLP 59.32 %	9,30,02,442	59.32 %	257 M ₹
Mukul Mahavir Agrawal 5.496 %	86,17,000	5.496 %	24 M ₹
HBM Partners AG (Investment Management) 3.546 %	55,60,116	3.546 %	15 M ₹
Massachusetts Institute of Technology Foundation 1.952 %	30,60,000	1.952 %	8 M ₹
HSBC Asset Management (India) Pvt Ltd. 0.9414 %	14,76,000	0.9414 %	4 M ₹
Motilal Oswal Asset Management Co. Ltd. 0.1416 %	2,22,030	0.1416 %	612 390 ₹
Groww Asset Management Ltd. 0.000682 %	1,070	0.000682 %	2 951 ₹
Deohooti Janmejay Vyas 0.000638 %	1,000	0.000638 %	2 758 ₹
Arpit Janmejay Vyas 0.000638 %	1,000	0.000638 %	2 758 ₹
Mansi J Vyas 0.000638 %	1,000	0.000638 %	2 758 ₹
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Other	61.27%
Individuals	5.5%
Institutional	4.63%
Unknown	28.6%

Based on 1000 largest holdings

Geographical origin of shareholders

India	60.4%
Individuals	5.5%
Switzerland	3.55%
United States	1.95%

Based on 1000 largest holdings

Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.

Employees

1,106

Sector

Pharmaceuticals

Calendar

06/02 - Q3 2026 Earnings Release (Projected)

More about the company